Literature DB >> 17005824

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Andreas H Groll1, Caron A Lyman, Vidmantas Petraitis, Ruta Petraitiene, Derek Armstrong, Diana Mickiene, Raul M Alfaro, Robert L Schaufele, Tin Sein, John Bacher, Thomas J Walsh.   

Abstract

We investigated the compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations in healthy rabbits. Cohorts of three to seven noninfected, catheterized rabbits received 1 mg of amphotericin B deoxycholate (DAMB) per kg of body weight or 5 mg of either amphotericin B colloidal dispersion (ABCD), amphotericin B lipid complex (ABLC), or liposomal amphotericin B (LAMB) per kg once daily for a total of 8 days. Following sparse serial plasma sampling, rabbits were sacrificed 24 h after the last dose, and epithelial lining fluid (ELF), pulmonary alveolar macrophages (PAM), and lung tissue were obtained. Pharmacokinetic parameters in plasma were derived by model-independent techniques, and concentrations in ELF and PAM were calculated based on the urea dilution method and macrophage cell volume, respectively. Mean amphotericin B concentrations +/- standard deviations (SD) in lung tissue and PAM were highest in ABLC-treated animals, exceeding concurrent plasma levels by 70- and 375-fold, respectively (in lung tissue, 16.24 +/- 1.62 versus 2.71 +/- 1.22, 6.29 +/- 1.17, and 6.32 +/- 0.57 microg/g for DAMB-, ABCD-, and LAMB-treated animals, respectively [P = 0.0029]; in PAM, 89.1 +/- 37.0 versus 8.92 +/- 2.89, 5.43 +/- 1.75, and 7.52 +/- 2.50 mug/ml for DAMB-, ABCD-, and LAMB-treated animals, respectively [P = 0.0246]). By comparison, drug concentrations in ELF were much lower than those achieved in lung tissue and PAM. Among the different cohorts, the highest ELF concentrations were found in LAMB-treated animals (2.28 +/- 1.43 versus 0.44 +/- 0.13, 0.68 +/- 0.27, and 0.90 +/- 0.28 microg/ml in DAMB-, ABCD-, and ABLC-treated animals, respectively [P = 0.0070]). In conclusion, amphotericin B and its lipid formulations displayed strikingly different patterns of disposition in lungs 24 h after dosing. Whereas the disposition of ABCD was overall not fundamentally different from that of DAMB, ABLC showed prominent accumulation in lung tissue and PAM, while LAMB achieved the highest concentrations in ELF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005824      PMCID: PMC1610093          DOI: 10.1128/AAC.00241-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Clinical pharmacology of antifungal compounds.

Authors:  Andreas H Groll; Juan C Gea-Banacloche; Axel Glasmacher; Gudrun Just-Nuebling; Georg Maschmeyer; Thomas J Walsh
Journal:  Infect Dis Clin North Am       Date:  2003-03       Impact factor: 5.982

Review 2.  Antifungal chemotherapy: advances and perspectives.

Authors:  Andreas H Groll; Thomas J Walsh
Journal:  Swiss Med Wkly       Date:  2002-06-15       Impact factor: 2.193

3.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits.

Authors:  T J Walsh; A J Jackson; J W Lee; M Amantea; T Sein; J Bacher; L Zech
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  Pulmonary extraction and accumulation of lipid formulations of amphotericin B.

Authors:  I Matot; R Pizov
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

6.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Authors:  A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

7.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 9.  Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.

Authors:  David Andes; Jack Anon; Michael R Jacobs; William A Craig
Journal:  Clin Lab Med       Date:  2004-06       Impact factor: 1.935

10.  Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes.

Authors:  A Schaffner; H Douglas; A Braude
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

View more
  26 in total

Review 1.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

Review 2.  Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.

Authors:  Matteo Bassetti; Franco Aversa; Filippo Ballerini; Fabio Benedetti; Alessandro Busca; Nicola Cascavilla; Ercole Concia; Andrea Tendas; Francesco Di Raimondo; Patrizio Mazza; Anna Maria Nosari; Giuseppe Rossi
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

3.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

4.  Invasive fungal infections in acute leukemia.

Authors:  Vijaya R Bhatt; George M Viola; Alessandra Ferrajoli
Journal:  Ther Adv Hematol       Date:  2011-08

5.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  Kinetics and intrapulmonary disposition of tilmicosin after single and repeated oral bolus administrations to rabbits.

Authors:  G Gallina; L Lucatello; I Drigo; M Cocchi; S Scandurra; F Agnoletti; C Montesissa
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

Review 7.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

8.  Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Authors:  Stefan Weiler; Gerda Falkensammer; Angelika Hammerer-Lercher; Markus Anliker; Helene Vogelsinger; Michael Joannidis; Stefan Dunzendorfer; Markus Stein; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

9.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

10.  Penetration of amphotericin B lipid formulations into pleural effusion.

Authors:  Stefan Weiler; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.